| INTRODUCTION
Prostate cancer is one of the most common non-cutaneous cancer in males, with approximately 417 000 new cases diagnosed in 2012 in Europe alone. 1 PSA testing has resulted in an increase in prostate cancer incidence and to a diagnostic migration toward smaller, lowgrade disease with low metastatic potential, and limited impact on mortality. [2] [3] [4] In the Western world, it is common practice to diagnose prostate cancer through transrectal, ultrasound-guided systematic needle biopsies (TRUS) in PSA-detected men. Clinico-pathological parameters obtained through this approach including serum PSA,
Gleason grade, and maximum cancer core length on biopsy are often used to stratify risk and guide patient management. In the last decade mpMRI has emerged as an important technique for characterising and targeting the biopsy of suspected prostate cancer, as it reduces the number of unnecessary biopsies and efficiently detects clinically significant targets without over-diagnosing insignificant disease. [5] [6] [7] [8] Incorporating tissue biomarkers in the patient stratification process could further refine the emerging imaging-based patient pathways, but selecting molecules for such purposes requires their parallel testing in very small amounts of diagnostic tissue. Tissue microarrays (TMAs) constructed from prostate needle biopsies are a promising tool for high-throughput biomarker development and validation. 9, 10 Numerous strategies have been proposed for maximising needle biopsy TMA performance, but a simple and productive approach is the vertical re-orientation of biopsy cores for the construction of high-density arrays. 11, 12 However, a recurring challenge in needle biopsy TMAs is the significant variability in their cancer content. This is generally due to (i) the considerable heterogeneity of prostate cancer; (ii) random tissue sampling approaches that often result in disease misrepresentation (which is not necessarily the case with TMAs derived from prostatectomy specimens); and (iii) tissue loss during sampling, fixation, embedding, or staining. These difficulties are further complicated by the scarcity of biopsy material, which is very precious and cannot be easily substituted if TMA quality is poor.
It follows that, for biomarker validation purposes, the ideal diagnostic needle biopsy TMA should (i) incorporate a large number of specimens; (ii) contain tissue from well-characterized prostate areas with clinically significant disease; (iii) have a high cancer detection rate for maximum performance; and (iv) produce results that can be correlated with imaging data. Here, we present the construction of a biopsy TMA from prostates thoroughly characterized using mpMRI and 5 mm transperineal mapping (TPM) biopsies. We divided the biopsy cores in segments such that only either benign or malignant tissue was included in a specific array position. To test our tissueselective TMAs, we performed IHC for routinely used prostate biomarkers and correlated IHC h-scores with imaging parameters and original pathology.
| MATERIALS AND METHODS

| Patient cohort
All prostate tissue was acquired during the PICTURE trial, a pairedcohort confirmatory study designed to assess the accuracy of mpMRI in detecting clinically significant cancer. 13 For this purpose, 249 men with a previous TRUS biopsy requiring a repeat evaluation underwent a 3T mpMRI followed by TPM biopsies of the entire prostate at 5 mm intervals. The likelihood of significant cancer by mpMRI was reported using the Likert scale, as previously defined. 14 In all MRI scans, the base, middle and apex of the prostate were divided in four quadrants resulting in Likert scores assigned to a total of 12 prostate areas for each patient. Ethical approval previously given for the study allowed the use of needle biopsy specimens for TMA construction as described below.
For each patient, the pathology report was reviewed and the biopsy cores with the highest Gleason score and/or the longest maximum cancer core length (MCCL) were identified and selected 
| Microarray construction
An overview of the TMA construction process is shown in Figure 1 . Arrayer was used to extract 1.5 × 6 mm wax cores containing the vertical 2 mm core segments from each donor block and place them in the recipient wax block. Benign and tumor core segments were randomly positioned 0.7 mm apart in a 6 × 10 format. Liver tissue and blank positions were also used for orientation purposes. Each newly constructed TMA block was placed on a glass slide for 40 min at 60°C in an incubator and then cooled on a cold plate for tempering.
Seven TMA blocks were produced and cut into 4 μm sections, with one slide every 50 retained for H&E staining and quality control.
| Immunohistochemistry (IHC)
FFPE TMA sections were deparaffinized and rehydrated with successive 5-min washes in xylene and alcohol (100, 90, and 70%). 
| IHC scoring
Digital images of the IHC slides were obtained using a Hamamatsu scanner. Each individual TMA core was assessed for the presence of cancer and h-scored by at least two independent investigators (HW, Pathological and radiological characteristics of the cohort: TPM biopsy reports were scrutinized and cores with the highest Gleason grade and/or maximum cancer core length identified. True benign biopsies or biopsies containing only prostatic intraepithelial neoplasia (PIN) from patients without any cancer were also included in the TMA. MRI images of the base, middle, and apex of each prostate were divided in quadrants and each quadrant assessed using a 5-point Likert scale for the likelihood of underlying clinically significant cancer (where scores of 4 or 5 denote a higher likelihood). For each TMA core, the corresponding Likert score for the sampled prostate quadrant was available.
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| Data analysis
All statistical analyses and visualization were performed in the R programming environment (http://www.R-project.org/, version 3.4.1).
Continuous data distributions (h-scores) were tested for normality using quantile-quantile plots and the Shapiro-Wilk test. Due to substantial non-normality of the h-score distributions, the paired Wilcoxon signed rank procedure was used to test for significant differences in h-scores between malignant and paired, adjacent benign tissue. Kruskal-Wallis analysis of variation was used for comparisons between multiple groups. All tests were two-sided and a statistical significance level of 0.01 was considered significant. FIGURE 1 TMA construction: Benign and malignant areas of 2 mm were identified within a biopsy core on H&E and selected for inclusion in the TMA (A). Each segment of core was divided according to the H&E cutting plan with a microtome blade, in order to obtain wax chips that contain either 2 mm of malignant or benign tissue core (B). The wax chips were marked on their edges for orientation, re-positioned vertically, and then embedded in a new paraffin donor block (C). All vertically re-embedded core segments are introduced into the final TMA block before tempering at 37°C for smoothing (D). In total, seven TMA slides were constructed and sectioned in their entirety, yielding 200-300 slides per TMA. The first slide of every 50 was stained with H&E for quality control while the rest were stored for immunohistochemistry after dipping in wax. [Color figure can be viewed at wileyonlinelibrary.com] 3 | RESULTS
| Performance measures
Although other methods of producing efficient biopsy TMAs have been described, data on their performance in terms of cancer detection rates are not comprehensive. [8] [9] [10] [11] For this TMA seven blocks were constructed containing 448 core segments in total. Slides were IHC stained against five biomarkers (PSA, PSMA, AMACR, p63, and MSMB), yielding a theoretical maximum of 2240 (5 × 448) stained core sections.
A summary of these results is given in Figure 2A and Table 3 ). In total, IHC and H&E appearances at a single level agreed in 1670 out of 1790 cases, with concordance in 349 cores stained for PSA, 324 for PSMA, 325 for p63, 342 for AMACR, and 330 for MSMB.
Concordance rates (ie, number of h-scored core sections with IHC-H&E
concordance/total number of h-scored core sections) were 94, 94, 95, 93, and 90% for each stain, respectively.
| IHC correlations with pathology and Gleason grade
Gleason grade is routinely used in indicate the aggressiveness of prostate cancer and markers preferentially diagnosing clinically significant disease (often characterized by the presence of ≥Gleason 4 pathology) are increasingly sought. For data analysis only patient matched pairs of malignant tissue and paired, adjacent benign tissue (from the same tissue block) were considered. The number of h-scored scored malignant-benign pairs was 105, 92, 101, 103, and 99 for PSA, PSMA, p63, AMACR, and MSMB, respectively, There statistically significant difference between the h-scores for malignant and paired benign tissue for PSA (P < 0.001), PSMA (P < 0.00001), p63
(P < 0.00001), AMACR (P < 0.00001), and MSMB (P < 0.00001) ( Figures 2B and 2C) . Overall, AMACR and PSMA h-scores were higher in tumor tissue compared to matched benign, whereas the opposite was true for p63, MSMB, and PSA. These differences were also seen when visualising h-scores for all cores (including unmatched) (Supplementary Figure S2) , although no statistical tests were performed as each group contained a mixture of paired and unpaired values.
As Gleason grade ≥4 is often associated with more aggressive disease each of the benign and malignant groups were analyzed separately to investigate h-score differences between different
Gleason grades at diagnosis (Figure 3 ). Non-parametric analysis of variation failed to demonstrate any significant h-score difference between both the benign and tumor tissues originating from cores with different Gleason grades indicating that protein expression of these markers was associated with tumorigenesis but not aggressiveness of disease.
| IHC correlations with mpMRI
mpMRI has been shown to efficiently diagnose clinically significant prostate tumors and is rapidly becoming a mainstay of prostate cancer diagnosis. Despite this, very few routinely used biomarkers have been studied in conjunction with mpMRI data. In this study paired h-scores were compared for different mpMRI Likert scores (Figure 4 ). When each benign and malignant group was divided to two Likert subgroups ("lower" Likert ≤ 3 vs "higher" Likert ≥ 4), there was a significant TMA quality assessment: All IHC was performed on the BondMax Autostainer for PSA, PSMA, p63, AMACR, and MSMB. Digital images of the IHC slides were obtained using a Hamamatsu scanner. Each individual TMA core was assessed for the presence of cancer and h-scored by at least two independent investigators (HW, VS, ZA) without prior knowledge of clinical data. The designation of a core section as "benign" or "malignant" was reassigned in cases of discrepancy with the H&E appearance in the original tissue block.
FIGURE 2 IHC for common prostate cancer biomarkers on paired samples: The seven TMA blocks were cut in their entirety and slides were wax dipped to prevent from oxidation. Slides at three levels (typically slide 50, 100, and 150) from each of the seven TMA slides were H&E stained and each core assessed for tumor or benign content. Concordance was measured as slides that had the same pathology at all three levels (dark green), two levels (pale green), one level (orange), and no levels (red). All IHC was performed on the BondMax Autostainer with staining shown in brown and nuclei are shown in blue. Representative images are shown for PSA, PSMA, p63, AMACR, and MSMB (20× magnification) (B). IHC for paired samples was analyzed using h-score method that takes into account staining intensity and the number of positively stained cells. Data for all samples (paired and unpaired) is shown in Supplementary Figure S1 . H-scores in tumor tissue (black) were compared to paired h-scores in benign tissue (gray) from the same biopsy block using a paired Wilcoxon signed rank test. The P-values and number of pairs are separately shown for each stain (C). [Color figure can be viewed at wileyonlinelibrary.com] difference between the paired h-scores for PSMA, p63, AMACR, and MSMB in both subgroups (P < 0.01). PSA was the exception: although there was a significant h-score difference in the "lower" Likert subgroup (P = 0.0023), there was no similar difference in the "higher"
Likert subgroup (P = 0.0945).
Different Likert scores were considered for each group (benign or malignant) separately (Supplementary Figure S1) . There was no significant h-score difference in benign tissue with different Likert scores assigned to the prostate area of origin for any biomarker (P > 0.1).
This was also the case for malignant tissue, although AMACR reached the level of marginal statistical significance (P = 0.03872), suggesting that there could be a difference in AMACR h-scores between malignant tissues from prostatic areas with different Likert scores.
| CONCLUSION
Despite the large number of emerging genomic models the current predictive models for stratifying prostate cancer patients for treatment remain based on clinico-pathological variables such as age, serum PSA levels, disease stage, and Gleason grade. 15 Using refined classification schemes which utilize biomarkers provides a route to increased predictive ability and personalized patient management. 16 Concordance was judged as partial when it agreed at two levels or full when all three levels exhibited the same pathology. Pathology concordance across the TMA. H&E slides were assessed every 50 slides over 150 slides of each TMA slide and assessed for tumor or benign pathology. Concordance was judged as partial when it agreed at two levels or full when all three levels exhibited the same pathology.
FIGURE 3 IHC h-scores versus Gleason grade: All IHC was analyzed using h-score method that takes into account staining intensity and the number of positively stained cells. H-scores for paired samples only in tumor tissue (black) and benign tissue (gray) are shown. All associations were tested within either benign or tumor groups using Kruskal-Wallis analysis of variation. The Pvalues and number of pairs are separately shown for each stain is often low or missing. In addition, true TMA performance is not routinely reported, at least meticulously.
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The TMA we describe here contains only patient-matched MRIcharacterized tissue cores containing the highest disease burden from 5 mm TPM biopsies or adjacent benign tissue. By using 2 mm core segments rather than entire needle biopsy cores we were able to ensure a significant degree of homogeneity and produce high-quality TMA measures (Table 2) . Excluding missing/not assessable cores or cores containing only stroma, the IHC and H&E concordance rate was greater than 90% for all stains. This uggests that, in instances where a core section ispresent for h-scoring and contains epithelial tissue, the scorer can be fairly confident that it contains benign or tumor tissue as originally intended in the H&E cutting plan. The numbers of missing, un-assessable, stroma-containing, concordant, or discordant cores were very similar between the five stains suggesting inter-slide reproducibility. We also demonstrated that tissue consistency was, on the whole, preserved along the entire TMA block, with concordance at two or more levels reaching almost 82%. TMA performance metrics are generally under-reported and our method of measuring performance could be widely adopted to facilitate comparisons between different needle biopsy TMA construction methods.
To demonstrate the tissue within the TMA is suitable for IHC it was used to assess expression of five widely used prostate biomarkers PSA, PSMA, p63, AMACR, and MSMB. [17] [18] [19] [20] The differential expression of tissue, high quality, resource with clinical, and radiological data which will allow validation of novel biomarkers correlated with imaging using a large number of biologically relevant patient samples.
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